Monoamine Oxidase (MAO)

An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4.

Also Known As:

Networked: 2414 relevant articles (82 outcomes, 324 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Youdim, Moussa B H: 35 articles (03/2015 - 04/2002)
2.	Amit, Tamar: 22 articles (03/2015 - 10/2003)
3.	Shih, Jean C: 18 articles (02/2015 - 05/2004)
4.	Weinreb, Orly: 16 articles (03/2015 - 09/2004)
5.	Bar-Am, Orit: 16 articles (03/2015 - 12/2003)
6.	Chen, Kevin: 14 articles (01/2014 - 05/2004)
7.	Petzer, Jacobus P: 13 articles (11/2015 - 01/2009)
8.	Unzeta, Mercedes: 13 articles (07/2014 - 08/2002)
9.	Ou, Xiao-Ming: 12 articles (11/2012 - 05/2004)
10.	Meyer, Jeffrey H: 11 articles (01/2016 - 12/2009)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2000 - "On the other hand, inhibition of MAO B appears to be an effective approach for the prevention and adjunct treatment of Parkinson's disease. " 01/01/2014 - "A meta-analysis was conducted from all published studies on the associations between monoamine oxidase B (MAOB) A644G polymorphism and Parkinson disease. " 01/01/2014 - "Many studies were conducted to assess the relationship between Monoamine oxidase B (MAOB) A644G polymorphism and susceptibility to Parkinson disease (PD). " 05/01/2012 - "A renewed interest in monoamine oxidase type B inhibitors in the treatment of Parkinson disease has emerged after recent clinical trials of agents in this class. " 09/11/2004 - "Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients."
2.	Alzheimer Disease (Alzheimer's Disease) 04/01/2015 - "Additionally, dual-target-directed compounds may find therapeutic value in Alzheimer's disease: antagonism of the A1 receptor may be beneficial in the treatment of cognitive dysfunction, while MAO-B inhibition may exhibit neuroprotective properties. " 01/01/1991 - "Monoamine oxidase B in brains from patients with Alzheimer's disease: a biochemical and autoradiographical study." 01/01/1990 - "Quantitative autoradiography, using 3H-deprenyl, was applied to study the regional localization of MAO-B in large cryosections from 3 control brains and 3 brains from patients with Alzheimer's disease (AD). " 12/16/2015 - "Recently, changes in concentrations of MAO-B have been proposed to be an in vivo marker of neuroinflammation associated with Alzheimer's disease. " 07/01/2015 - "A series of compounds with monoamine oxidase inhibition and biometal chelation activities were designed, synthesised and evaluated as agents against Alzheimer's disease. "
3.	Body Weight (Weight, Body) 03/01/2008 - "Goutengsan could increase the brain index, cut down the rate of death, stable increase of body weight, promote the endogenous antioxidant activity, enhance the clearance of lipid peroxide and other metabolic waste, inhibit the MAO-B activity, reduced the leakage of LDH and maintain the content of NO at a normal level. " 01/01/2013 - "Body weight, waist circumference and total fat mass decreased significantly in response to the intervention in both MAO and MHO women (all p < 0.001). " 03/01/2008 - "After administration, the death rate, body weight, training scores, brain index, MAO-B, SOD, GSH-Px in brain and NO, LDH in serum were determined. " 09/17/2004 - "The MAO A/B KO mice showed reduced body weight compared with wild type mice. " 10/01/1984 - "The monoamine oxidase activity in the cerebral hemispheres decreased significantly after 2, 4, 8 and 16 hr of 6-amino-nicotinamide (35 mg/kg body weight, i.p.) administration. "
4.	Schizophrenia (Dementia Praecox) 05/01/1978 - "MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia." 05/01/2014 - "Association study between monoamine oxidase A (MAOA) gene polymorphisms and schizophrenia: lack of association with schizophrenia and possible association with affective disturbances of schizophrenia." 07/01/2012 - "This study was undertaken to analyze DNA methylation profiling at the monoamine oxidase A (MAOA) locus, in order to determine whether abnormal DNA methylation is involved in the development of schizophrenia. " 06/01/2012 - "In this clinical study, we investigated the relationship between the AQP-4 polymorphism and drug response in schizophrenia under the control of the MAOA (monoamine oxidase A) promoter gene. " 01/01/2011 - "Association study of monoamine oxidase A/B genes and schizophrenia in Han Chinese."
5.	Panic Disorder (Panic Attack) 04/01/1999 - "Together with the observation that inhibition of monoamine oxidase A is clinically effective in the treatment of panic disorder these findings suggest that increased monoamine oxidase A activity is a risk factor for panic disorder in female patients." 04/01/1999 - "One class of drugs effective in the treatment of panic disorder is represented by monoamine oxidase A inhibitors. " 04/01/1999 - "In the present study we investigated a novel repeat polymorphism in the promoter of the monoamine oxidase A gene for association with panic disorder in two independent samples (German sample, n = 80; Italian sample, n = 129). " 09/01/1988 - "The results do not support some studies that have shown elevated MAO activity in patients with panic attacks. " 10/01/2012 - "The monoamine oxidase A (MAOA) gene has been suggested as a prime candidate in the pathogenesis of panic disorder. "

Related Drugs and Biologics

1.	Monoamine Oxidase (MAO)
2.	Selegiline (E250)
3.	rasagiline (Azilect)
4.	Levodopa (L Dopa)
5.	Monoamine Oxidase Inhibitors (Monoamine Oxidase Inhibitor)
6.	Pentylenetetrazole (Metrazol)
7.	Dopamine (Intropin)
8.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)
9.	Dopamine Agonists (Dopamine Agonist)
10.	Smoke

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Investigational Therapies (Experimental Therapy)
3.	Drug Therapy (Chemotherapy)
4.	Vagotomy
5.	Chinese Traditional Medicine (Traditional Chinese Medicine)